Fig. 2From: Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximabSpecificity of anti-α-Gal IgE fluoroenzyme-immunoassay. FEIA ImmunoCap o215 tests were performed on 10 patients’ sera with or without Cetuximab or Rituximab addition. Each symbol represents a single patient. * p < 0.05; ns, non-significantBack to article page